Skip to main content Skip to accessibility
This website is not compatible with your web browser. You should install a newer browser. If you live in Jersey and need help upgrading call the States of Jersey web team on 440099.
Government of Jerseygov.je

Information and public services for the Island of Jersey

L'înformâtion et les sèrvices publyis pouor I'Île dé Jèrri

  • Choose the service you want to log in to:

  • gov.je

    Update your notification preferences

  • one.gov.je

    Access government services

  • CAESAR

    Clear goods through customs or claim relief

  • Talentlink

    View or update your States of Jersey job application

Prescribed List: Changes from 1 March 2015

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

  • demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision

  • providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made 19 February 2015:

Decision Reference: MD-S-2015-0014

Decision Summary Title :

DS_PBAC 20 January 2015

Date of Decision Summary:

12 February 2015

Decision Summary Author:

Prescribing Advisor

Decision Summary:

Public or Exempt?

Public

Type of Report:

Oral or Written?

Written

Person Giving

Oral Report:

N/A

Written Report

Title :

WR_PBAC Report 20 January 2015

Date of Written Report:

12 February 2015

Written Report Author:

Prescribing Advisor

Written Report :

Public or Exempt?

FoI (J) Law 2011  Part 5 (33) Commercial Interests

Subject: Changes to be made to the Prescribed List (Jersey) as at 1 March 2015

Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make the following amendments to the Prescribed List as recommended by the PBAC.  The addition of five new medicines

 

  • Canagliflozin tablet 100mg, 300mg; canagliflozin tablet 50mg/metformin 850mg, canagliflozin tablet  50mg/metformin 1g for the treatment of type II diabetes
  • Dapagliflozin tablet 5mg, 10mg; dapagliflozin 5mg/metformin 850mg, dapagliflozin 5mg/metformin 1g tablet for the treatment of type II diabetes
  • Triptorelin injection 3mg, 11.25mg, 22.5mg for the treatment of prostate cancer
  • Colecalciferol tablet 20mcg (800 units) for the prevention of vitamin D deficiency
  • Fostair Nexthaler containing beclometasone 100mcg/formoterol 6mcg in a dry powder breath-actuated inhaler for the treatment of asthma

 

Two products, dorzolamide eye drops and dorzolamide/timolol eye drops, were recommended for reimbursement as a generic product only.

 

In addition, the Committee recommended amendment of existing entries in the Prescribed List for sitagliptin, to include 25mg and 50mg strength tablets, and to replace methotrexate pre-filled syringe (now discontinued) with methotrexate pre-filled Pen device. 

 

These changes will have effect from 1 March 2015.

Reason(s) for Decision:

The Pharmaceutical Benefit Advisory Committee (PBAC) met on 20 January 2015 and has provided the Minister with a written report setting out its recommendations in respect of amendments to the Prescribed List.  Furthermore, the changes reflect current evidence and expert advice, and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs at a proportionate cost to the Fund.

Resource Implications:   The estimated financial impact of these recommendations in total is £5,000 per annum.

Action required:  Policy Principal to issue public notice listing amendments and notify all approved medical practitioners and approved contractors.

Signature:

 

Position:

Minister

Date Signed:

 

 

Date of Decision (If different from Date Signed):

 

Back to top
rating button